

Marek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5733605/publications.pdf>

Version: 2024-02-01

73
papers

5,055
citations

117625

34
h-index

91884

69
g-index

84
all docs

84
docs citations

84
times ranked

5354
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccines "The way forward. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 15-16.	5.7	3
2	EAACI Biologicals Guidelines "Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 17-38.	5.7	19
3	Climate change: A call to action for the United Nations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1087-1090.	5.7	26
4	The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. International Immunology, 2022, 34, 177-188.	4.0	27
5	Development and validation of combined symptom-medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
6	Climate change and global health: A call to more research and more action. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1389-1407.	5.7	60
7	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals "EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	5.7	12
8	AllergoOncology: Danger signals in allergology and oncology: "European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2594-2617.	5.7	5
9	Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
10	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air [®] real-world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
11	Serum Allergen-Specific IgE among Pediatric Patients with Primary Immunodeficiency. Children, 2022, 9, 466.	1.5	0
12	Comparison of rhinitis treatments using MASK-air [®] data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
13	Placebo effects in allergen immunotherapy "An EAACI Task Force Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 629-647.	5.7	31
14	Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 71-89.	5.7	41
15	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic "An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
16	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
17	Real-life impact of COVID-19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2776-2784.	5.7	19
18	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA "EAACI "GA ² LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31

#	ARTICLE	IF	CITATIONS
19	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1805-1812.	3.8	14
20	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23
21	Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3307-3313.	5.7	92
22	EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1629-1639.	5.7	99
23	ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1624-1628.	5.7	66
24	Spermidine and spermine exert protective effects within the lung. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00837.	2.4	31
25	Inhaled corticosteroids in early COVID-19 – A tale of many facets. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3540-3542.	5.7	3
26	Advances and highlights in asthma in 2021. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3390-3407.	5.7	75
27	COVID-19 pandemic and allergen immunotherapy – an EAACI survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3504-3516.	5.7	26
28	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
29	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	2.9	272
30	Biologics in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologics, San Lorenzo de El Escorial, Madrid, 2019. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 936-940.	5.7	12
31	State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 746-760.	5.7	42
32	Considerations on biologics for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2764-2774.	5.7	75
33	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	3.2	97
34	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	5.7	114
35	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives – A report of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2445-2476.	5.7	132
36	EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1899-1901.	5.7	3

#	ARTICLE	IF	CITATIONS
37	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EEAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	5.7	87
38	In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan- An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2161-2169.	5.7	23
39	Food and drug allergy, and anaphylaxis in EAACI journals (2018). <i>Pediatric Allergy and Immunology</i> , 2019, 30, 785-794.	2.6	11
40	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
41	Highlights and recent developments in airway diseases in EAACI journals (2018). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2329-2341.	5.7	9
42	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
43	Prioritizing research challenges and funding for allergy and asthma and the need for translational research- The European Strategic Forum on Allergic Diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2064-2076.	5.7	39
44	EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 855-873.	5.7	191
45	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
46	Perspectives in allergen immunotherapy: 2019 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 3-25.	5.7	113
47	Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. <i>Nature Communications</i> , 2019, 10, 5711.	12.8	141
48	Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 449-463.	5.7	77
49	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergologie Select</i> , 2019, 3, 22-50.	3.1	70
50	Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 382-390.e7.	2.9	44
51	EAACI guidelines on allergen immunotherapy: Prevention of allergy. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 728-745.	2.6	171
52	A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 476-483.	1.6	49
53	Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. <i>Clinical and Translational Allergy</i> , 2017, 7, 25.	3.2	56
54	Validation of the Global Allergy and Asthma European Network (GA 2 LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1158-1166.	2.9	32

#	ARTICLE	IF	CITATIONS
55	Allergen Immunotherapy: Past, Present, and Future. <i>Allergy, Asthma and Immunology Research</i> , 2016, 8, 191.	2.9	70
56	Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitisâ€”PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1347-1358.	2.9	249
57	Histamine-secreting microbes are increased in the gut of adult asthma patients. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1491-1494.e7.	2.9	109
58	Allergen immunotherapy for allergic asthma: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 5.	3.2	15
59	International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 358-368.	2.9	199
60	T-cell regulation during viral and nonviral asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 194-197.e9.	2.9	21
61	International consensus on allergy immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 556-568.	2.9	427
62	Sublingual immunotherapy (SLIT) â€” indications, mechanism, and efficacy Position paper prepared by the Section of Immunotherapy, Polish Society of Allergy. <i>Annals of Agricultural and Environmental Medicine</i> , 2015, 23, 44-53.	1.0	22
63	Allergen-Specific Immunotherapy in Asthma. <i>Current Treatment Options in Allergy</i> , 2014, 1, 213-219.	2.2	30
64	Mechanisms of Allergen-Specific Immunotherapy and Novel Ways for Vaccine Development. <i>Allergology International</i> , 2013, 62, 425-433.	3.3	63
65	The Future of Allergen-Specific Immunotherapy. <i>Drug Information Journal</i> , 2012, 46, 683-687.	0.5	2
66	Recombinant allergens. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1534-1543.	3.3	31
67	Immunological mechanisms of allergen-specific immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 725-732.	5.7	197
68	T-cell Subset Regulation in Atopy. <i>Current Allergy and Asthma Reports</i> , 2011, 11, 139-145.	5.3	89
69	Histamine Receptors in Immune Regulation and Allergen-Specific Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 245-259.	1.9	25
70	Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex?? Quattro). <i>Drugs</i> , 2006, 66, 939-940.	10.9	0
71	Clinical Results from Vaccination With Recombinant Grass Pollen Allergens. <i>Clinical and Developmental Immunology</i> , 2006, 13, 389-394.	3.3	7
72	Allergen-specific immunotherapy with recombinant grass pollen allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 608-613.	2.9	466

#	ARTICLE	IF	CITATIONS
73	Treatment with Ebastine Changes Expression of Histamine H1 and H2 Receptor mRNA on Peripheral Blood Mononuclear Cells. Clinical Drug Investigation, 2002, 22, 25-30.	2.2	2